Swiss drug maker Novartis has invested in trial document automation services firm Yseop joining existing backers like Eli Lilly and NextStage AM.
The investment – financial terms of which were not disclosed – will fund Yesop’s stated aim of automating the entire document process across pharma, from preclinical trials all the way through regulatory approval.
CEO Emmanuel Walckenaer said “Our investors and clients understand the value Yseop brings by automating various aspects of medical writing and how impactful Generative AI capabilities can be when applied across all of life sciences."
“This further strategic investment adds significant value to Yseop as we look to build out our Generative AI technology and scale it across pharma content development.”
Yesop uses a type of artificial intelligence – generative AI – which is capable of generating text, images, or other media, using generative models. Generative AI models – like the widely used ChatGTP platform – can learn the patterns and structure of their input training data and then generate new data that has similar characteristics.
In drug research the aim is to automate the production of clinical trial documents – everything from clinical study reports and patient narratives through to summaries of clinical safety – thereby making the submission process as streamlined as possible.
This year, Paris, France headquartered Yseop claims to have generated 10,000+ reports and eliminated tens of thousands of hours of writing and review time for the CROs and clinical trial sponsors with which it works.
News of the investment comes a little over a year after French drug maker Sanofi teamed with Yseop to use its natural language generation (NLG) capabilities to accelerate clinical study submission processes.
Prior to that, in May last year, Eli Lilly signed a deal to use Yseop’s Augmented Analyst to transform data into high-quality narratives and regulatory submission reports, at scale.
Unsplash/precondo